Literature DB >> 22887128

Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.

Leila Choucha-Snouber1, Caroline Aninat, Laurent Grsicom, Geoffrey Madalinski, Céline Brochot, Paul Emile Poleni, Florence Razan, Christiane Guguen Guillouzo, Cécile Legallais, Anne Corlu, Eric Leclerc.   

Abstract

In this article, we present a liver-kidney co-culture model in a micro fluidic biochip. The liver was modeled using HepG2/C3a and HepaRG cell lines and the kidney using MDCK cell lines. To demonstrate the synergic interaction between both organs, we investigated the effect of ifosfamide, an anticancerous drug. Ifosfamide is a prodrug which is metabolized by the liver to isophosforamide mustard, an active metabolite. This metabolism process also leads to the formation of chloroacetaldehyde, a nephrotoxic metabolite and acrolein a urotoxic one. In the biochips of MDCK cultures, we did not detect any nephrotoxic effects after 72 h of 50 µM ifosfamide exposure. However, in the liver-kidney biochips, the same 72 h exposure leads to a nephrotoxicity illustrated by a reduction of the number of MDCK cells (up to 30% in the HepaRG-MDCK) when compared to untreated co-cultures or treated MDCK monocultures. The reduction of the MDCK cell number was not related to a modification of the cell cycle repartition in ifosfamide treated cases when compared to controls. The ifosfamide biotransformation into 3-dechloroethylifosfamide, an equimolar byproduct of the chloroacetaldehyde production, was detected by mass spectrometry at a rate of apparition of 0.3 ± 0.1 and 1.1 ± 0.3 pg/h/biochips in HepaRG monocultures and HepaRG-MDCK co-cultures respectively. Any metabolite was detected in HepG2/C3a cultures. Furthermore, the ifosfamide treatment in HepaRG-MDCK co-culture system triggered an increase in the intracellular calcium release in MDCK cells on contrary to the treatment on MDCK monocultures. As 3-dechloroethylifosfamide is not toxic, we have tested the effect of equimolar choloroacetaldehyde concentration onto the MDCK cells. At this concentration, we found a quite similar calcium perturbation and MDCK nephrotoxicity via a reduction of 30% of final cell numbers such as in the ifosfamide HepaRG-MDCK co-culture experiments. Our results suggest that ifosfamide nephrotoxicity in a liver-kidney micro fluidic co-culture model using HepaRG-MDCK cells is induced by the metabolism of ifosfamide into chloroacetaldehyde whereas this pathway is not functional in HepG2/C3a-MDCK model. This study demonstrates the interest in the development of systemic organ-organ interactions using micro fluidic biochips. It also illustrated their potential in future predictive toxicity model using in vitro models as alternative methods.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887128     DOI: 10.1002/bit.24707

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  25 in total

Review 1.  Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure.

Authors:  Jong Hwan Sung; Balaji Srinivasan; Mandy Brigitte Esch; William T McLamb; Catia Bernabini; Michael L Shuler; James J Hickman
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

2.  Microfluidic organs-on-chips.

Authors:  Sangeeta N Bhatia; Donald E Ingber
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 3.  Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions.

Authors:  Shyam Sundhar Bale; Laura Moore; Martin Yarmush; Rohit Jindal
Journal:  Tissue Eng Part B Rev       Date:  2016-06-01       Impact factor: 6.389

Review 4.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

Review 5.  Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges.

Authors:  Ying I Wang; Carlos Carmona; James J Hickman; Michael L Shuler
Journal:  Adv Healthc Mater       Date:  2017-12-04       Impact factor: 9.933

Review 6.  How multi-organ microdevices can help foster drug development.

Authors:  Mandy B Esch; Alec S T Smith; Jean-Matthieu Prot; Carlota Oleaga; James J Hickman; Michael L Shuler
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

Review 7.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

8.  Application of chemical reaction engineering principles to 'body-on-a-chip' systems.

Authors:  Jong Hwan Sung; Ying I Wang; Jung Hun Kim; Jong Min Lee; Michael L Shuler
Journal:  AIChE J       Date:  2018-10-12       Impact factor: 3.993

Review 9.  Engineered Liver Platforms for Different Phases of Drug Development.

Authors:  Brenton R Ware; Salman R Khetani
Journal:  Trends Biotechnol       Date:  2016-09-02       Impact factor: 19.536

Review 10.  Tissue-engineered kidney disease models.

Authors:  Teresa M Desrochers; Erica Palma; David L Kaplan
Journal:  Adv Drug Deliv Rev       Date:  2013-12-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.